[Form 4] Gossamer Bio, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Gossamer Bio, Inc. (GOSS) – Form 4 filing dated 06/26/2025

Non-employee director Skye Drynan received an option grant for 115,000 shares of common stock with an exercise price of $1.36 per share on 06/25/2025. The award was made under the company’s Non-Employee Director Compensation Program.

The option vests 100 % on the earlier of (a) the first anniversary of the grant date or (b) the next annual meeting of stockholders, subject to continued board service. The director now beneficially owns 115,000 derivative securities; no common shares were reported as acquired or sold. Ownership is listed as direct.

No cash transactions, open-market purchases, or sales were disclosed. The filing represents a routine equity incentive and does not indicate any change in the company’s operational outlook or financial condition.

Insights

Financial Analyst

TL;DR: Routine director option grant; neutral impact on GOSS valuation.

This Form 4 documents a standard, non-employee director stock-option grant—115,000 shares at $1.36, vesting within roughly one year. Such awards are typical for board compensation and do not involve an open-market purchase or sale, so they provide limited insight into insider sentiment. The strike is near current market levels, implying normal alignment with shareholder interests rather than opportunistic pricing. No immediate dilution occurs because options are unexercised. Overall, the disclosure is administrative and immaterial to near-term valuation or liquidity considerations.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Drynan Skye

(Last) (First) (Middle)

3115 MERRYFIELD ROW, SUITE 120

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Gossamer Bio, Inc. [ GOSS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.36	06/25/2025		A		115,000(1)		(2)	06/24/2035	Common Stock	115,000	$0	115,000	D

Explanation of Responses:

1. Award made pursuant to Non-Employee Director Compensation Program.

2. The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

Remarks:

	/s/ Jeff Boerneke, Attorney-in-Fact	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did GOSS disclose in the latest Form 4 filing?

Gossamer Bio reported a grant of 115,000 stock options to director Skye Drynan at a $1.36 strike price.

When do the newly granted GOSS options vest?

The options fully vest on the earlier of the first anniversary of 06/25/2025 or the next annual stockholder meeting.

Did the reporting person buy or sell any GOSS common shares?

No. The filing shows only an acquisition of stock options; no common shares were purchased or sold.

How many derivative securities does the director now own?

Following the grant, Skye Drynan beneficially owns 115,000 stock options.

Is this Form 4 likely to impact GOSS share price?

The transaction appears routine and immaterial; therefore, it is unlikely to materially affect the stock price.